文献速递心外重症与机械循环支持

HeartMate 3左心室辅助装置的一年结局

One-year outcomes with the HeartMate 3 left ventricular assist device.
PubMed 文献 · J Thorac Cardiovasc Surg · 2018-02-13

该前瞻性单中心研究纳入27例连续植入HeartMate 3左心室辅助装置的患者,随访1年完整。1年生存率为85.2%,未观察到泵血栓和卒中,主要并发症为左心室辅助装置相关感染(22.2%)。

要点

  • 27例患者1年生存率85.2%,其中3例心脏移植、3例死亡。
  • 随访1年内无泵血栓、无卒中,无泵技术故障,无需更换泵。
  • 主要并发症为左心室辅助装置相关感染,发生率为22.2%。

核心结论

  • 在该队列中,HeartMate 3植入后1年生存率为85%,1年泵血栓率和卒中率均为0%,中期结果良好。

研究设计与样本

  • 前瞻性单中心队列研究,连续纳入27例接受HeartMate 3左心室辅助装置植入的患者,随访1年完整。

主要发现

  • 1年内3例患者接受心脏移植,3例死亡;30天生存率88.9%,6个月生存率85.2%,1年生存率85.2%。
  • 研究组内未观察到泵血栓和卒中。
  • 观察到1例胃肠道出血(3.7%),1例植入后右心衰竭(3.7%)。
  • 未记录到泵的技术并发症,无需更换泵。
  • 主要并发症为左心室辅助装置相关感染(22.2%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The HeartMate 3 (HM3; Abbott Laboratories, Lake Forest, Ill) left ventricular assist device (LVAD) received its Conformité Européenne mark for Europe in October 2015 and is currently under investigation of the Food and Drug Administration to gain approval in the United States. Within this study, we present the first real-world experiences, 1-year outcomes, and adverse events of a single-center cohort treated with the HM3. METHODS: We prospectively studied midterm results of 27 consecutive patients receiving the HM3 at a single institution. After HM 3 implantation, survival, causes of death, and complications were recorded for all patients. Follow up was 100% complete. RESULTS: Twenty-seven patients were enrolled into the study. Within 1 year after HM3 implantation, 3 patients underwent heart transplantation and 3 patients died. Thirty-day survival was 88.9%, 6-month 85.2%, and 1-year survival 85.2%. No pump thrombosis and no strokes were observed within the study group. One incident of gastrointestinal bleeding was observed (3.7%). Right heart failure was diagnosed in 1 patient after HM3 implantation (3.7%). No technical complications of the pump were documented. No pump exchanges were necessary. The main complication was LVAD-related infection (22.2%). CONCLUSIONS: The novel LVAD HM3 has already shown excellent Conformité Européenne mark trial results. Within this cohort, 1-year survival after HM3 implantation was 85%. The HM3 showed excellent midterm results with 0% stroke and 0% pump thrombosis rates 1 year after implantation.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Hanke JS, Dogan G, Zoch A, et al. One-year outcomes with the HeartMate 3 left ventricular assist device. J Thorac Cardiovasc Surg. 2018. PMID: 29525258. doi:10.1016/j.jtcvs.2018.01.083

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。